| Document |
Document Title |
|
WO/2022/238403A1 |
The present invention relates to a composition comprising at least the following molecules: oleic acid, palmitic acid, lauric acid, linoleic acid, azelaic acid, farnesylcysteine, palmitoleic acid, cholesterol, thioctic acid, myristic aci...
|
|
WO/2022/237890A1 |
An azepine-type fused ring compound and a pharmaceutical use thereof. Specifically, involved are an azepine-type fused ring compound shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising sam...
|
|
WO/2022/239862A1 |
Provided are extracellular vesicles derived from cells that show reduced graft rejection and have a physiological activity. The composition according to the present invention contains extracellular vesicles of a regenerative cell popul...
|
|
WO/2022/239863A1 |
The present invention addresses the problem of providing an antisense oligomer capable of treating Werner's syndrome without direct mutated gene repair, or a pharmacologically acceptable salt of the antisense oligomer. The present inve...
|
|
WO/2022/234850A1 |
The present invention relates to: a composition which contains a compound represented by formula (1) or a salt thereof, or a solvate of the same; a liquid additive; and an optional oily component.
|
|
WO/2022/234852A1 |
Discovered were: a cyclic peptide compound that interacts with Ras; and a pharmaceutical composition comprising the cyclic peptide compound, a salt thereof, or a solvate thereof.
|
|
WO/2022/233625A2 |
Compositions and methods that use a combination of NARH and NR to produce intracellular NAD+/NADH. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions c...
|
|
WO/2022/234867A1 |
The present invention provides a compound represented by formula [I] having an MMP 7-inhibiting action or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/234855A1 |
The present invention provides a method for designing an oligonucleotide having a reduced central toxicity, the method being characterized by including a step for substituting a carbon atom at the 5' position of a sugar portion of at lea...
|
|
WO/2022/235050A1 |
The present invention relates to a composition for inhibiting tumor growth, containing an extract of Sanguisorba officinalis as an active ingredient. It has been identified that a Sanguisorba officinalis extract binds to PD-L1 on cancer ...
|
|
WO/2022/233460A1 |
The present invention belongs to the field of medicine, and more precisely to the field of medicine useful in the treatment of cardiac diseases with contributing mitochondrial dysfunction. The present invention relates to a composition a...
|
|
WO/2022/234853A1 |
The present inventors found a cyclic compound and an oligopeptide compound that selectively inhibit KRAS. The present inventors further found an oligopeptide compound and a non-natural amino acid that are useful for producing the cyclic ...
|
|
WO/2022/233872A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein n, m, A1, A2, A3, A4, A5, A6, L1, L2, R1, R2, R3, Y and Z are defined herein. Also provided herein are pharmaceutical compositions compris...
|
|
WO/2022/230987A1 |
A prophylactic or therapeutic agent for myopathy, containing a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.
|
|
WO/2022/230487A1 |
The purpose of the present invention is to provide: a composition for increasing red blood cells and/or hemoglobin; a composition for preventing or ameliorating anemia; a composition for improving endurance; an anti-fatigue composition; ...
|
|
WO/2022/232002A1 |
Aspects of the disclosure relates to composition and methods for treating Hermansky-Pudlak syndrome-associated pulmonary fibrosis in a subject. The disclosure is based, in part, on isolated nucleic acids and rAAVs encoding a Hermansky-Pu...
|
|
WO/2022/230494A1 |
The purpose of the present invention is to provide a composition for stimulating immune cell metabolism, a composition for immune activation, a method for stimulating immune cell metabolism, and a method for immune activation. The presen...
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/230851A1 |
The present invention provides a novel prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis. Provided is a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis.
|
|
WO/2022/230489A1 |
The purpose of the present invention is to provide an anti-anxiety composition for humans and a method for preventing or improving anxiety symptoms. The present invention pertains to an anti-anxiety composition for humans that comprises ...
|
|
WO/2022/232356A1 |
Aspects disclosed herein include a method for treatment of a subject, the method comprising: topically administering a melanin formulation having an artificial melanin material (thereby administering artificial melanin material) to (or, ...
|
|
WO/2022/228223A1 |
An engineered mitochondria and a preparation method therefor. The engineered mitochondria binds to an outer membrane of an exogenous mitochondria by means of an exogenous cell membrane. The preparation method of the engineered mitochondr...
|
|
WO/2022/225045A1 |
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The present invention provides a therapeutic or prophylactic agent for cachexia accompanied by g...
|
|
WO/2022/224172A1 |
The invention relates to the use of Aviptadil or a functional derivative or a precursor thereof alone or in combination with Alpha Lipoic Acid or a functional derivative or a precursor thereof as (a) therapeutic agent(s) for the prophyla...
|
|
WO/2022/223099A1 |
Suggested is a composition comprising or consisting of (a) Cannabidiol and optionally (b) Bisabolol for use as a medicament for prophylaxis and treatment of various dysfunctions of human skin triggered particularly by stress.
|
|
WO/2022/224820A1 |
The present invention provides: a compound represented by formula I, formula I', formula II, or formula II'; and a composition that is for regulating circadian rhythm and that contains said compound or an Agrocybe erebia culture.
|
|
WO/2022/225297A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of cachexia, comprising a Lysimachiae Herba, Raphani Semen or Buddlejae Flos extract. The Lysimachiae Herba, Raphani Semen or Buddlejae Flos ext...
|
|
WO/2022/224372A1 |
The present application provides a novel means for treating ornithine transcarbamylase deficiency. More specifically, the present application provides a modified adeno-associated virus vector which expresses ornithine transcarbamylase so...
|
|
WO/2022/225203A1 |
The present invention relates to a liposome comprising phosphatidylserine and an RGD motif, and a composition for modulating macrophage activity, comprising phosphatidylserine and an RGD motif. A liposome, and a composition for modulatin...
|
|
WO/2022/226172A1 |
The present disclosure relates to compounds which increase y-oscillations in the brain. The disclosure further relates to methods of treating neurodegenerative diseases or disorders with the compounds disclosed herein.
|
|
WO/2022/225259A1 |
The present invention relates to an anticancer composition containing as an active ingredient a compound inducing cell senescence and cell death. The compound of the present invention can discriminate cancer cells and normal cells and in...
|
|
WO/2022/226100A1 |
The present disclosure provides, inter alia, antibodies with covalently attached biocompatible polymeric moieties, that are useful in treating various diseases such as cancer and autoimmune disorders.
|
|
WO/2022/225007A1 |
The present invention addresses the problem of providing an actinium-225-labeled anti-MUC5AC humanized antibody exhibiting excellent specificity to mucin subtype 5AC (MUC5AC), excellent clustering in tumors, and reduced kidney toxicity. ...
|
|
WO/2022/225960A1 |
The invention provides a method for applying diarylhydantoin compounds, including flutamide, bicalutamide, enzalutamide, apalutamide, and proxalutamide, to treat sepsis and conditions that mimic sepsis.
|
|
WO/2022/224644A1 |
Provided is a novel material that can inhibit TARC related to pathogenesis of various inflammatory diseases, and that is effective in therapy and the like for, for example, atopic dermatitis. This material is a kumis-derived exosome–co...
|
|
WO/2022/224962A1 |
The present invention addresses the problem of providing a pharmaceutical composition / drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascula...
|
|
WO/2022/224776A1 |
A lipid decrease promoter containing IPQ and/or a salt thereof as an active ingredient.
|
|
WO/2022/218237A1 |
A granule capable of nourishing Yin, nourishing internal organs and cooling blood is prepared from a component A and a component B. The active pharmaceutical ingredients of the component A comprise Fresh Rehmannia Root, Prepared Rehmanni...
|
|
WO/2022/220179A1 |
[Problem] To provide a novel preparation for periodontal tissues, which enables a treatment to be performed by a simple operation, can achieve high periodontal tissue regeneration performance, and can achieve a high regeneration effect f...
|
|
WO/2022/219172A1 |
The present invention relates to inhibitors of hexokinase-dependent glucose carrier-mediated glucose uptake (Warbicins) that can be used to inhibit proliferation of cancer cells and other cells with an overactive glucose uptake and catab...
|
|
WO/2022/221522A1 |
Disclosure herein are an implantable cell containing device, its subcomponent scaffold, methods of making the same and their methods of use. The implantable cell containing device includes a scaffold and a cell -containing hydrogel encap...
|
|
WO/2022/220147A1 |
The present invention provides a muscle atrophy inhibition composition. Specifically, the present invention provides a muscle atrophy inhibitor that includes a CXCL10 expression inhibitor as an active ingredient.
|
|
WO/2022/220227A1 |
Provided is a tetrahydropyridopyrimidine compound which has Axl inhibitory activity and selectively inhibits Axl over Mer.
|
|
WO/2022/220265A1 |
Provided is a novel use of S-1-propenylcysteine, a salt thereof or a composition containing the same. A Sirtuin or Klotho activator or expression enhancer that comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
|
|
WO/2022/215568A1 |
The purpose of the present invention is to provide a novel technique for directly promoting muscle synthesis without physical activity and preventing muscle atrophy. Provided is: a muscle synthesis promoting agent or muscle atrophy pre...
|
|
WO/2022/215441A1 |
Provided is a novel active ingredient derived from carob and a usage therefor. The present invention is a compound represented by formula (I) or a salt thereof, or a solvate of the compound or the salt.
|
|
WO/2022/214025A1 |
Disclosed in the present invention are a pegylated lipid, a preparation method therefor, a liposome containing the pegylated lipid, a pharmaceutical composition containing the liposome, a preparation thereof, and the use thereof, belongi...
|
|
WO/2022/215619A1 |
The present invention addresses the problem of providing a composition capable of effectively promoting GLP-1 secretion. This problem can be solved by providing a composition for promoting GLP-1 secretion that comprises, as active ingred...
|
|
WO/2022/215754A1 |
Provided is a bicyclic pyridine derivative. A compound represented by formula I [wherein: X represents an oxygen atom, a sulfur atom, NR or CR'R"; n is 0 or 1; R1, R2a, R2b, R2c, R2d, R, R' and R" independently represent a hydrogen atom,...
|
|
WO/2022/215622A1 |
The present invention pertains to: a pyrrole-imidazole polyamide compound that has a specific structure, or a salt thereof; a membrane protein gene expression inhibitor that includes the compound or a salt thereof; and a cancer metastasi...
|
